The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis
- Registration Number
- NCT01496196
- Lead Sponsor
- Meir Medical Center
- Brief Summary
Hemoptysis is defined as the expectoration of blood from respiratory tract, a spectrum that varies from blood-streaking of sputum to coughing up large amounts of pure blood.
Massive hemoptysis variably defined as the expectoration of 100-600 ml over 24-h period.
The most common site of bleeding is the tracheobronchial tree, which can be affected by inflammation (acute or chronic bronchitis, bronchiectasis) or by neoplasm ( bronchogenic carcinoma, endobronchial metastatic carcinoma, bronchial carcinoid tumor). The bronchial arteries, which originate either from aorta or from intercostal arteries, and are part of the high-pressure systemic circulation, are the source of bleeding in bronchitis or bronchiectasis or endo bronchial tumors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
- Age > 18
- Hemodynamicaly stable
- Hemoptysis of varying etiologies
- Coumadin treatment will be switched to clexane or heparine
- Age < 18
- Hemodinamicaly unstable
- Massive hemoptysis ( > 200 ml / day)
- Renal failure: creatinine > 3, renal replacement treatment
- Hepatic failure: bilirubin > 2 mg/dl, AST > 3 of upper normal limit level
- Coagulation disorders, INR> 2.
- Hypesensitivity to tranexamic acid
- Pregnant woman
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description tranexamic tranexamic acid placebo arm tranexamic acid-500 mg/5 ml 3-4 times a day tranexamic acid tranexamic acid arm: inhalations of tranexamic acid 500 mg/5 ml 3-4 times a day
- Primary Outcome Measures
Name Time Method bleeding stops 1 year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Pulmonary department, Meir Medical Center
🇮🇱Kfar Saba, Israel